| Document |
Document Title |
|
WO/2022/240952A1 |
Oligonucleotide conjugates are provided herein that inhibit or reduce expression of target genes in the neurons of the central nervous system. Also provided are compositions including the same and uses thereof, particularly uses relating...
|
|
WO/2022/237747A1 |
Disclosed is a compound of formula (I), and a stereoisomer, a pharmaceutically acceptable salt, a solvate, a co-crystal or a deuterated product thereof, or a pharmaceutical composition containing same, and the use thereof as a CD73 antag...
|
|
WO/2022/238816A1 |
Bicyclic heterocyclic compounds and derivatives thereof that have antiviral properties are disclosed. Pharmaceutical compositions and pharmaceutical formulations in unit dosage form suitable for the delivery of the compounds to a subject...
|
|
WO/2022/234598A1 |
This invention provides a process for the preparation of orthogonally protected ribose derivative. Which are further used as donor for the synthesis of N4-hydroxy cytidine and its derivatives by using commercially available materials und...
|
|
WO/2022/235838A1 |
Disclosed herein is a modified ribonucleotide comprising a nucleoside comprising N4- acetylcytidine and/or 5-hydroxymethyluridine, and polyribonucleotides comprising the same. Also provided herein are compositions comprising a polyribonu...
|
|
WO/2022/233923A1 |
The present invention discloses synthesis of nicotinamide riboside chloride (NRCl). More particularly, the present invention describes cost effective and industrially scalable process for the synthesis of NRCl in amorphous form.
|
|
WO/2022/227117A1 |
Disclosed are a method for synthesizing vidarabine monophosphate and the use thereof, which belong to the field of drug synthesis. The synthesis method comprises subjecting 5-iodo-2-((phosphonooxy)methyl)-4-(tosyloxy)tetrahydrofuran-
3-y...
|
|
WO/2022/232622A1 |
Alkylsulfenyl thiocarbonates capable of releasing hydropersulfides (RSSH) and carbonyl sulfide (COS) under physiological conditions and their use for treating or preventing disorders, diseases, or conditions associated with oxidative str...
|
|
WO/2022/227873A1 |
The present invention relates to the technical field of new medicines, and provides a selenium-containing ribose compound having KGA inhibitory activity and a synthesis method therefor and an application thereof. The present invention de...
|
|
WO/2022/225827A1 |
Novel forms of 2-amino-9-[(2R,5R,7R,8S,10R,12aR,14R,15S,15aR,16R)-14-(6-ami
no-9H-purin-9-yl)-15,16-difluoro-2,10-dihydroxy-2,10-disulfi
dooctahydro-12H-5,8-methanofuro[3,2-l][1,3,6,9,11,2,10]penta
oxadiphospha-cyclotetradecin-7-yl]-1,9-...
|
|
WO/2022/220019A1 |
The purpose of the present invention is to provide a method for synthesizing a long-chain nucleic acid (particularly DNA) with high accuracy. The present invention provides a method for synthesizing a long-chain nucleic acid, the method ...
|
|
WO/2022/221241A1 |
Compounds comprising 5-position modified pyrimidines are provided. Further, polynucleotides, such as aptamers, comprising at least one 5-position modified pyrimidine are provided. Methods of selecting and using such polynucleotides, such...
|
|
WO/2022/218274A1 |
The present invention relates to a nucleoside analog as shown in the following formula and a use thereof. Specifically, the present invention relates to a nucleoside analog as shown in the following formula, or a pharmaceutically accepta...
|
|
WO/2022/218943A1 |
This specification discloses novel phosphate compounds of formula (I) useful for labelling RNA in-cellulo. The phosphates are spontaneously taken up by cells and may be used as substrates for RNA synthesis once across the cell membrane. ...
|
|
WO/2022/214692A1 |
A novel pseudo solid phase protecting group and methods for the synthesis of oligonucleotides and oligonucleotide conjugates are provided. The pseudo solid phase protecting group is represented by formula II wherein: * indicates the poin...
|
|
WO/2022/216577A1 |
Novel forms of 2-amino-9-[(2R,5R,7R,8S,10R,12aR,14R,15S,15aR,16R)-14-(6-ami
no-9H-purin-9-yl)-15,16-difluoro-2,10-dihydroxy-2,10-disulfi
dooctahydro-12H-5,8-methanofuro[3,2-l][1,3,6,9,11,2,10]penta
oxa-diphosphacyclotetradecin-7-yl]-1,9-...
|
|
WO/2022/212442A1 |
Provided herein are methods of making trinucleotides and tetranucleotides for use as 5' mRNA caps. The methods utilize a novel "top-down" strategy and provide for synthesis of oligonucleotides with higher yields and increased efficiency ...
|
|
WO/2022/204777A1 |
The present invention relates to antiviral compounds selected from cytokinins, their nucleosides and nucleotide analogs, and their prodrugs as inhibitors of viral RNA synthesis, or their salts, solvates, derivatives, or even combinations...
|
|
WO/2022/206922A1 |
The present invention relates to the field of nucleic acid sequencing. Specifically, provided in the present invention is a nucleotide analogue for sequencing. The nucleotide analogue carries a linker on the base or the ribose ring 3'-OH...
|
|
WO/2022/208508A1 |
The present invention provides a scalable two-step synthesis of molnupiravir. The reaction sequence involves the use of commercially easily available cytidine (1), and molnupiravir is formed through direct hydroxy amination of the cytidi...
|
|
WO/2022/211627A1 |
This invention relates to compounds that are useful as inhibitors, in particular as inhibitors of Nicotinamide N-methyltransferase (NNMT), and formulations composing such compounds. The compounds and formulations may be used as a medicam...
|
|
WO/2022/212230A1 |
The present invention relates to efficient processes useful in the preparation of fluorinated cyclic dinucleosides, such as [P(R)]-2'-deoxy-2'-fluoro-5'-O-[(R)-hydroxymercaptophosphiny
l]-P-thio-β-D-arabino-adenylyl-(3'→5')-3'-deoxy-3...
|
|
WO/2022/204770A1 |
The present invention relates to antiviral compounds selected from cytokinins, their nucleosides and nucleotide analogs, and their prodrugs as inhibitors of viral RNA synthesis, or their salts, solvates, derivatives, or even combinations...
|
|
WO/2022/203427A1 |
The present invention relates to: an adenosine derivative capable of acting as an antagonist on A2A and A3 adenosine receptors through the introduction of substituents into carbons at the 2nd and 8th positions and 6th and/or 9th amine(s)...
|
|
WO/2022/194924A1 |
This invention relates to compounds of Formula (I) useful as synthons for a general synthetic method for making chiral phosphorothioates, to their preparation and to their use in a robust large scale process for making P-chiral phosphoro...
|
|
WO/2022/189846A1 |
The present invention relates to medicine, and in particular to the treatment of viral infections, more particularly to inhibitors of viral mRNA cap methyltransf erases (MTases). Even more particularly, the invention relates to adenosylm...
|
|
WO/2022/190915A1 |
Provided are: a novel compound having improved in-vivo efficacy and antitumor activity of a curcumin derivative, or a salt thereof; and an antitumor activator containing the same as an active ingredient. The present invention is a compou...
|
|
WO/2022/189459A2 |
The present invention relates to beta D-galactopyranose compound of formula (I). Wherein the pyranose ring is β-D-galactopyranose, and these compounds are high affinity galectin-3 inhibitors for use in treatment of inflammation; fibrosi...
|
|
WO/2022/188903A1 |
The present disclosure relates to 3'3' cyclic dinucleotides containing isonucleotidic units, their pharmaceutically acceptable salts, their pharmaceutical composition and combinations of said substances and other medicaments or pharmaceu...
|
|
WO/2022/187312A1 |
The present disclosure provides a process of separating designated oligomeric compounds from sample solutions comprising at least one contaminant. In certain embodiments, the designated oligomeric compounds comprise a modified oligonucle...
|
|
WO/2022/183281A1 |
Among other things, in general, compositions and methods of treatment for muscular dystrophy and other diseases are disclosed. A method of treatment of a subject is disclosed, in which fatty acid utilization is improved. The method inclu...
|
|
WO/2022/182604A1 |
The invention relates to compounds of Formula (I), salts thereof, pharmaceutical compositions thereof, as well as methods of treating or preventing HIV in subjects.
|
|
WO/2022/183066A1 |
The present application is directed to, in part, nucleotide analogs with a novel design of a 3'-OH reversible terminator that comprises an enzyme-cleavable linkage.
|
|
WO/2022/183109A1 |
An electroporation buffer comprising: a solvent; a sugar; a chloride salt; and a buffering agent. In certain embodiments: the solvent is water; the sugar is glucose or mannitol; the chloride salt is potassium chloride (KCl) or magnesium ...
|
|
WO/2022/183081A1 |
Compounds useful for forming nucleic acids having the structure of Formula (I). Each of R1 or R2 is independently selected from hydrogen, a protecting group, or a phosphoramidite group. R3 is selected from H, F, O-C1-6 alkyl, O-MOE and a...
|
|
WO/2022/175685A1 |
The present invention relates to a compound according to Formula (la) or (lb) wherein R1; R3; Y and X are defined herein, and their use in methods of nucleic acid synthesis. Disclosed herein is a method of reducing the deamination of the...
|
|
WO/2022/174351A1 |
Novel and known substituted purine compounds and salts thereof act as adenosine A2a receptor (A2aR) antagonists for cancer immunotherapy, depression, anxiety, multiple sclerosis, NASH, scleroderma, ADHD, Alzheimer's and Parkinsons. Pharm...
|
|
WO/2022/175684A1 |
The present invention relates to a compound according to Formula (1a) or (1b): wherein R1; R2; R3 X and Y are defined herein, and their use in methods of nucleic acid synthesis.
|
|
WO/2022/171561A1 |
The present invention relates to a D-galactopyranose compound of formula (1) wherein the pyranose ring is beta-D-galactopyranose, and these compounds are high affinity galectin-1 and/or 3 inhibitors for use in treatment of inflammation; ...
|
|
WO/2022/174194A1 |
Disclosed are halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections. Such viral infections can i...
|
|
WO/2022/168106A1 |
Disclosed herein is a process for synthesis of Molnupiravir from cytidine of using a lipase for esterification reaction. The process comprises of reacting compound of formula II with acetone in presence of sulphuric acid to obtain compou...
|
|
WO/2022/168107A1 |
Disclosed herein is the enzymatic process for synthesis of Molnupiravir intermediate, 5'-isobutylester of cytidine acetonide. The process employs cytidine acetonide as starting material to prepare 5'-isobutylester of cytidine acetonide. ...
|
|
WO/2022/166581A1 |
A nucleotide derivative, a pharmaceutical composition thereof, and a use thereof. Specifically disclosed are a nucleotide derivative represented by formula (I) or a tautomer, a stereoisomer, a solvate, a pharmaceutically acceptable salt ...
|
|
WO/2022/163764A1 |
Provided is a method for producing an imidazopyridine derivative represented by formula (I), wherein, in formula (I), X is H, a substituted or unsubstituted propenyl group, a substituted or unsubstituted propinyl group, or a substituted ...
|
|
WO/2022/165358A1 |
A process is provided for microencapsulating nicotinamide riboside (NR), and other NR derivatives by using ethyl cellulose which may be polymerized in a particular manner. Further, compositions comprising NR or derivatives thereof microe...
|
|
WO/2022/164941A1 |
Advantageous isolated morphic Form III of the hemi-sulfate salt of AT-527 that exhibits a faster rate of dissolution over the amorphous form leading to increased bioavailability and thus efficacy for therapeutic administration in a solid...
|
|
WO/2022/163846A1 |
The purpose of the present invention is to provide: a novel stereoselective method for producing a cyclic dinucleotide derivative that can be used for an antibody-immunostimulator conjugate; and a production intermediate thereof. Another...
|
|
WO/2022/159872A1 |
Disclosed herein are adenosine derivative prodrugs and compositions thereof that can be used for the treatment of HIV infection or RNA virus infection.
|
|
WO/2022/159877A1 |
The present disclosure is directed to methods of treating or preventing RNA virus infections and retroviral diseases, such as HIV and AIDS, comprising administering to a subject in need an effective amount of (a) a capsid inhibitor and (...
|
|
WO/2022/159811A1 |
This invention provides compounds of Formulae (I), (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH), (IJ), (II), (III), (IIIA), and (IIIB); pharmaceutically acceptable salts and solvates thereof; and compositions thereof. This invention fu...
|
